BDBM50505843 CHEMBL4449589::US11174245, # I-235

SMILES CC(C)(O)Cn1c2ccccc2[nH]\c1=N/C(=O)c1ccnc(c1)-c1cccnc1

InChI Key InChIKey=OGMCMDPGFSKWAJ-UHFFFAOYSA-N

Data  8 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 50505843   

TargetEpidermal growth factor receptor(Human)
Boehringer Ingelheim Rcv

Curated by ChEMBL
LigandPNGBDBM50505843(CHEMBL4449589 | US11174245, # I-235)
Affinity DataIC50: 353nMAssay Description:Inhibition of GST-fusion tagged EGFR L858R/T790M/C797S triple mutant (unknown origin) (696 to 1022 residues) expressed in insect cells assessed as de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/19/2021
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Boehringer Ingelheim Rcv

Curated by ChEMBL
LigandPNGBDBM50505843(CHEMBL4449589 | US11174245, # I-235)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of human recombinant GST-tagged wild type EGFR expressed in baculovirus expression system assessed as decrease in phosphorylation of ULigh...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/19/2021
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Mouse)
Boehringer Ingelheim Rcv

Curated by ChEMBL
LigandPNGBDBM50505843(CHEMBL4449589 | US11174245, # I-235)
Affinity DataIC50: 3.60E+3nMAssay Description:Inhibition of wild type EGFR in mouse BAF3 cells assessed as reduction in cell proliferation incubated for 72 hrs by Celltiter-Glo luminescent cell v...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/19/2021
Entry Details Article
PubMed
TargetEpidermal growth factor receptor [695-745,751-1022,T790M,C797S](Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM50505843(CHEMBL4449589 | US11174245, # I-235)
Affinity DataIC50: 57.2nMAssay Description:5 μL of EGFR enzyme form in assay buffer (50 mM HEPES pH 7.3, 10 mM MgCl2, 1 mM EGTA, 0.01% Tween 20, 2 mM DTT) are dispensed into columns 1-23,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [695-1022,T790M,C797S,L858R](Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM50505843(CHEMBL4449589 | US11174245, # I-235)
Affinity DataIC50: 10.7nMAssay Description:5 μL of EGFR enzyme form in assay buffer (50 mM HEPES pH 7.3, 10 mM MgCl2, 1 mM EGTA, 0.01% Tween 20, 2 mM DTT) are dispensed into columns 1-23,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [695-1022,T790M,C797S,L858R](Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM50505843(CHEMBL4449589 | US11174245, # I-235)
Affinity DataIC50: 440nMAssay Description:5 μL of EGFR enzyme form in assay buffer (50 mM HEPES pH 7.3, 10 mM MgCl2, 1 mM EGTA, 0.01% Tween 20, 2 mM DTT) are dispensed into columns 1-23,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [695-1022](Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM50505843(CHEMBL4449589 | US11174245, # I-235)
Affinity DataIC50: 8.85E+3nMAssay Description:5 μL of EGFR enzyme form in assay buffer (50 mM HEPES pH 7.3, 10 mM MgCl2, 1 mM EGTA, 0.01% Tween 20, 2 mM DTT) are dispensed into columns 1-23,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [695-1022](Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM50505843(CHEMBL4449589 | US11174245, # I-235)
Affinity DataIC50: 1.00E+5nMAssay Description:5 μL of EGFR enzyme form in assay buffer (50 mM HEPES pH 7.3, 10 mM MgCl2, 1 mM EGTA, 0.01% Tween 20, 2 mM DTT) are dispensed into columns 1-23,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2022
Entry Details
Go to US Patent